PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease

MT newswire2026/09/21 20:54

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:54 PM EDT, 09/21/2026 (MT Newswires) -- PTC Therapeutics (PTCT) said late Monday it completed the acquisition of ST-920, a gene therapy for Fabry disease, a rare genetic disorder, from Sangamo Therapeutics. A rolling biologics license application submission to the US Food and Drug Administration for accelerated approval of the therapy is expected to be completed in Q4, according to a statement.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nvidia will further increase its investment in SB Energy Inc., a data center infrastructure provider backed by SoftBank Group, ahead of SB Energy’s planned US initial public offering (IPO). Nvidia plans to invest an additional $1.5 billion, bringing its total investment in SB Energy to $3 billion.

智通财经•2026/09/21 22:36

Woodward agrees to sell Santa Clarita campus, legacy aerospace product lines; deal to close in fiscal 2027

Bitget•2026/09/21 21:15